Application of multiplexed pharmacokinetic immunoassay to quantify drug forms and coadministered biologics.

Meso Scale Discovery U-PLEX provides an opportunity to develop multiplexed pharmacokinetic (PK) immunoassays. Two case studies demonstrate the utility of multiplexed PK methods. Development of PK ligand-binding assays quantify of nonclinical plasma concentrations of a biotherapeutic that has degraded due to biotransformation, and clinical serum concentrations from two biotherapeutics spiked into a single sample.